CDK9 and ovarian cancer: In previous studies, the synergetic effect of olaparib, a PARP inhibitor, combined with CDKI-73, a CDK9 inhibitor, was reported in BRCA1-proficient ovarian cancer cells; the combination resulted in a reduction of BRCA1 expression and recruitment to DNA damage sites [61].